Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 701–800 of 1,002
Girardi, D. M., Pacifico, J. P. M., de Amorim, F. P. L. G., Fernandes, G. D. S., Teixeira, M. C., & Pereira, A. A. L. (2020) · Pharmaceuticals · doi:10.3390/ph14010028 · Cited by 31
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Rahma, O. E., Tyan, K., Giobbie‐Hurder, A., Brohl, A. S., Bedard, P. L., Renouf, D. J., Sharon, E., STREICHER, H. Z., Hathaway, E. S., Cunningham, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003569 · Cited by 31
“…monoclonal antibody that binds to PD-1 receptor, has been shown to effectively produce significant antitumor immune responses in advanced melanoma and renal cell carcinoma (RCC) 18 19 but plays less of a role in tumors with low immune infiltrates such as colorectal cancer (CRC) and ovarian cancer.”
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma
Bootsma, M. L., McKay, R. R., Emamekhoo, H., Bade, R. M., Schehr, J. L., Mannino, M. C., Singh, A., Wolfe, S. K., Schultz, Z. D., Sperger, J. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00219 · Cited by 32
High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
Kuo, A. M.-S., & Markova, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.898790 · Cited by 35
Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Sharma, R., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.766869 · Cited by 36
Baldini, C., Danlos, F., Varga, A., Texier, M., Halse, H. M., Mouraud, S., Cassard, L., Champiat, S., Signolle, N., Vuagnat, P., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02423-0 · Cited by 31
Shah, N. J., Cook, M. R., Wu, T., Ari, S. L., Blackburn, M. J., Serzan, M. T., Alaoui, A., Ahn, J., & Atkins, M. B. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7020 · Cited by 32
Self-citationYip, W., Ghoreifi, A., Gerald, T., Lee, R. A., Howard, J. M., Asghar, A. M., Khanna, A., Cai, J., Aron, M., Gill, I. S., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.03.003 · Cited by 33
Cheng, B., Xie, M., Zhou, Y. C., Tian, L., Liu, W., Yu, W., Jia, M., Yu, S., Chen, L., Dai, R., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01423-z · Cited by 32
“Although immunotherapy alone or combined with TKI is a popular way to treat metastatic ccRCC [6, 7], TKI such as pazopanib is still utilized as the first line therapy to treat metastatic ccRCC in developing countries, showing promising outcomes [8–11].”
BackgroundShafqat, A., Omer, M. H., Ahmed, E. N., Mushtaq, A. H., Ijaz, E., Ahmed, Z., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200941 · Cited by 36
“Clinical trials evaluating the ef fi cacy of ICI + anti-angiogenic regimens have shown superior outcomes in various cancers, based on which the FDA has approved the use of these combinations for the treatment of renal cell carcinoma, HCC, NSCLC, and endometrial carcinoma (198 – 201).”
BackgroundGeorge, D. J., Hessel, C., Halabi, S., Michaelson, M. D., Hahn, O. M., Walsh, M. K., Picus, J., Small, E. J., Dakhil, S. R., Feldman, D. R., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0316 · Cited by 30
Chow, P., Liu, S., Chang, Y.-W., Kuo, K.-L., Lin, W., & Huang, K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.005 · Cited by 30
Self-citationImmune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons
Aquilanti, E., & Brastianos, P. K. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa095 · Cited by 31
Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era
Ishihara, H., Takagi, T., Kondo, T., Fukuda, H., Tachibana, H., Yoshida, K., Iizuka, J., Kobayashi, H., Ishida, H., & Tanabe, K. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.08.011 · Cited by 30
Dizman, N., Govindarajan, A., Zengin, Z. B., Meza, L., Tripathi, N., Sayegh, N., Castro, D. V., Chan, E. H., Lee, K. O., Prajapati, S. R., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.06.004 · Cited by 35
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 31
Gu, L., Peng, C. Y., Li, H., Jia, T., Chen, X., Wang, H., Du, S., Tang, L., Liang, Q., Wang, B., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104316 · Cited by 29
Investigational MET inhibitors to treat Renal cell carcinoma
Nandagopal, L., Sonpavde, G., & Agarwal, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1673366 · Cited by 29
Wang, R., Zheng, J., Shao, X., Ishii, Y., Roy, A., Bello, A., Lee, R., Zhang, J. H., Wind‐Rotolo, M., & Feng, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0819-2 · Cited by 29
Ocular side effects of checkpoint inhibitors
Alba‐Linero, C., & Alba, E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.01.001 · Cited by 32
Biomarker-Oriented Therapy in Bladder and Renal Cancer
Scholtes, M., Alberts, A. R., Iflé, I. G., Verhagen, P. C. M. S., van der Veldt, A. A. M., & Zuiverloon, T. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062832 · Cited by 30
“Within the Keynote-426 study (NCT02853331) combination treatment of pembrolizumab (ICI) and axitinib (VEGFR-TKI) is compared with sunitinib [95].”
BackgroundInfluentialSite-specific Response to Nivolumab in Renal Cell Carcinoma
Negishi, T., Furubayashi, N., Nakagawa, T., Nishiyama, N., Kitamura, H., Hori, Y., Kuroiwa, K., Son, Y., Seki, N., Tomoda, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14913 · Cited by 29
Advances in Targeting Cutaneous Melanoma
Kasakovski, D., Skrygan, M., Gambichler, T., & Susok, L. (2021) · Cancers · doi:10.3390/cancers13092090 · Cited by 35
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
Agulnik, M., Schulte, B. C., Robinson, S. I., Hirbe, A. C., Kozak, K. R., Chawla, S. P., Attia, S., RADEMAKER, A. W., Zhang, H., Abbinanti, S. E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.027 · Cited by 29
Labadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 37
“These combinations include axitinib plus pembrolizumab evaluated in the KEYNOTE-426 clinical trial, lenvatinib plus pembrolizumab evaluated in the CLEAR clinical trial, axitinib plus avelumab evaluated in the JAVELIN Renal 101 clinical trial and cabozantinib plus nivolumab evaluated in the CheckMate-9ER clinical trial…”
MethodComandone, A., Vana, F., Comandone, T., & Tucci, M. (2021) · Cancers · doi:10.3390/cancers13235896 · Cited by 31
“The side effects reported were as expected for the pembrolizumab plus axitinib combination: pulmonary infections, anemia, thrombocytopenia, anaphylaxis, hypothyroidism/hyperthyroidism, loss of appetite, hypocalcemia, peripheral neuropathy, cardiac arrhythmia, diarrhoea, epistasis, skin rash, myalgia, arthralgia, and f…”
BackgroundFGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
Lv, Z., Cui, B., Huang, X., Feng, H., Wang, T., Wang, H.-F., Xuan, Y., Li, H., Ma, X., Huang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756843 · Cited by 29
“Immunotherapy-based combinations have become standard of care in patients with advanced RCC, and have shown efficacy and overall survival benefits in the first-line metastatic setting (12, 13).”
BackgroundFirst-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
Gulati, S., Labaki, C., Karachaliou, G. S., Choueiri, T. K., & Zhang, T. (2022) · The Oncologist · doi:10.1093/oncolo/oyab056 · Cited by 32
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future
Kasherman, L., Siu, D. H. W., Woodford, R. G., & Harris, C. A. (2022) · Cancers · doi:10.3390/cancers14061406 · Cited by 32
“KEYNOTE-426 [4] NCT02853331 Previously untreated, advanced RCC with clear-cell component with or without sarcomatoid features Any IMDC risk group Arm 1: Pembrolizumab 200 mg IV Q3W and axitinib 5 mg PO twice daily Arm 2: Sunitinib 50 mg PO daily, 4 weeks on treatment followed by 2 weeks off treatment 861 PFS mPFS: pem…”
BackgroundResultInfluentialBarth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Posch, F., Lipp, R., Halm, M., Szkandera, J., Balić, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4675 · Cited by 31
Wang, Q., Tang, H., Luo, X., Chen, J., Zhang, X., Li, X., Li, Y., Chen, Y., Xu, Y., & Han, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890150 · Cited by 31
Mulgaonkar, A., Elias, R. M., Woolford, L., Guan, B., Nham, K., Kapur, P., Christie, A. L., Tcheuyap, V. T., Singla, N., Bowman, I. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1547 · Cited by 31
Gao, J., Ye, F., Han, F., Jiang, H., & Zhang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956679 · Cited by 30
“Some targeted therapies have shown decent treatment effects in ccRCC patients, including sorafenib and axitinib (9, 10).”
BackgroundZarrabi, K. K., Handorf, E. A., Miron, B., Zibelman, M. R., Anari, F. M., Ghatalia, P., Plimack, E. R., & Geynisman, D. M. (2022) · The Oncologist · doi:10.1093/oncolo/oyac195 · Cited by 32
Self-citationBrackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 30
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
Dibajnia, P., Cardenas, L. M., & Lalani, A. A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178217 · Cited by 32
Chakiryan, N. H., Kim, Y., Berglund, A., Chang, A. C., Kimmel, G. J., Hajiran, A. J., Nguyen, J. V., Segura, C. M., Saeed‐Vafa, D., Katende, E. N., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006195 · Cited by 32
Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study
Duarte, C., Hu, J., Beuselinck, B., Panian, J. A., Weise, N., Dizman, N., Collier, K. A., Rathi, N., Li, H., Elias, R. M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102018 · Cited by 32
Checkpoint inhibitors and anti-angiogenic agents: a winning combination
Brest, P., Mograbi, B., Pagès, G., Hofman, P. M., & Milano, G. A. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02437-1 · Cited by 33
Starzer, A. M., Wolff, L., Popov, P., Kiesewetter, B., Preusser, M., & Berghoff, A. S. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102718 · Cited by 30
Ishihara, H., Takagi, T., Kondo, T., Fukuda, H., Tachibana, H., Yoshida, K., Iizuka, J., Okumi, M., Ishida, H., & Tanabe, K. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.12.008 · Cited by 29
Testa, U., Pelosi, E., & Castelli, G. (2020) · Medicines · doi:10.3390/medicines7080044 · Cited by 33
Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871252 · Cited by 28
Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma
Cao, F., Xu, Z., Zhang, S., & Pang, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01880-0 · Cited by 30
“Additionally, the combination of nivolumab and cabozantinib showed substantial bene fi ts over sunitinib, encompassing improvements in progression-free survival, overall survival, and the likelihood of treatment response [63 – 65].”
BackgroundReprogramming cancer immunity with next-generation combination therapies
Kyriakidis, N. C., Echeverría, C. E., Bautista, J., Rivera-Orellana, S., Ramos-Medina, M. J., Salazar-Santoliva, C., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Guerrero, S. X., & López‐Cortés, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1652047 · Cited by 33
Targeting the MAPK Pathway in Cancer
Kadasah, S. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010214 · Cited by 31
“The therapy combining axitinib with pembrolizumab and avelumab has led to improved overall survival, progression-free survival, and response rates in renal cell carcinoma [90,91].”
Ascierto, P. A., Bifulco, C. B., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0798-3 · Cited by 31
“The combination has also shown significantly improved OS and PFS versus sunitinib as first-line therapy for advanced or metastatic RCC in the KEYNOTE-426 trial [24].”
BackgroundEnhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
Dolan, M., Mastri, M., Tracz, A., Christensen, J. G., Chatta, G. S., & Ebos, J. M. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220101 · Cited by 28
Brighi, N., Farolfi, A., Conteduca, V., Gurioli, G., Gargiulo, S., Gallá, V., Schepisi, G., Lolli, C., Casadei, C., & Giorgi, U. D. (2019) · Cancers · doi:10.3390/cancers11121935 · Cited by 28
Pal, S. K., McDermott, D. F., Atkins, M. B., Escudier, B. J., Rini, B. I., Motzer, R. J., Fong, L. H., Joseph, R. W., Oudard, S. M., Ravaud, A., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15058 · Cited by 28
Self-citationCheckpoint inhibitors in metastatic papillary renal cell carcinoma
Vries-Brilland, M. D., McDermott, D. F., Suárez, C., Powles, T. B., Gross‐Goupil, M., Ravaud, A., Flippot, R., Escudier, B. J., & Albiges, L. K. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102228 · Cited by 30
Self-citationGüven, D. C., Acar, R., Yekedüz, E., Bilgetekin, İ., Baytemür, N. K., Erol, C., Ceylan, F., Şendur, M. A. N., Demırcı, U., Ürün, Y., et al. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100760 · Cited by 28
Klümper, N., Schmucker, P., Hahn, O., Hoeh, B., Mattigk, A., Banek, S., Ellinger, J., Heinzelbecker, J., Sikic, D., Eckstein, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1358 · Cited by 30
Fontes-Sousa, M., Magalhães, H., Oliveira, A., Carneiro, F., dos Reis, A. F. P., Madeira, P. S., & Meireles, S. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02007-y · Cited by 29
“The KEYNOTE-426 population included approximately 31% of patients with a favourable-risk prognosis, as defined by the IMDC criteria [30, 31].”
BackgroundInfluentialDelire, B., Martin, E. D., Meunier, L., Larrey, D. G., & Horsmans, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786174 · Cited by 30
He, H., Jin, Z., Dai, J., Wang, H., Sun, J., & Xu, D. (2022) · Cancer Medicine · doi:10.1002/cam4.5449 · Cited by 32
Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer
Wu, L., Bai, S., Huang, J., Cui, G., Li, Q., Wang, J., Du, X., Fu, W., Li, C., Wei, W., et al. (2023) · Cancers · doi:10.3390/cancers15123221 · Cited by 31
“Clinical trials of Imbrave150 and Keynote426 showed that targeting blood vessels was an effective strategy to modulate the tumor microenvironment and improve the anti-cancer effect of immune checkpoint inhibitors in hepatic and renal cancers [46,47].”
BackgroundESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
Čufer, T., & Kosty, M. P. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101631 · Cited by 30
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 31
“Axitinib (vascular endothelial growth factor receptor-VEGFR-kinase) and Pembrolizumab (a humanized anti-PD-L1 mAb) have shown improved overall survival (OS) and progression-free survival (PFS) in advanced renal cell carcinoma patients [29].”
BackgroundSEOM clinical guideline for treatment of kidney cancer (2019)
Lázaro-Quintela, M., Valderrama, B. P., Suárez, C., de Velasco, G., Beato, C., Chirivella, I., del Alba, A. G., Laínez, N., Méndez-Vidal, M. J., & Arranz, J. Á. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02285-7 · Cited by 31
Ding, D., Hu, H., Shi, Y., She, L., Yao, L., Zhu, Y., Zeng, S., Shen, L., & Huang, J. (2020) · The Oncologist · doi:10.1002/onco.13522 · Cited by 31
“The incidence rates of AEs in the model came from the KEYNOTE-426 trial data [13].”
BackgroundMethodInfluentialPatients' perspective on digital technologies in advanced genitourinary cancers
Rodler, S., Buchner, A., Stief, C. G., Heinemann, V., Staehler, M., & Casuscelli, J. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.018 · Cited by 27
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun, Y., Yinwang, E., Wang, S., Wang, Z., Wang, F., Xue, Y., Zhang, W., Zhao, S., Mou, H., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02104-w · Cited by 34
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 31
The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma
Quinn, A. E., Bell, S. D., Marrah, A. J., Wakefield, M. R., & Fang, Y. (2024) · Cancers · doi:10.3390/cancers16234034 · Cited by 30
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies
Roviello, G., Aquino, I. D. G., Vascotto, I. A., Venturi, G., D’Angelo, A., Winchler, C., Guarino, A., Cacioppo, S., Modesti, M., Mela, M. M., et al. (2024) · Genes · doi:10.3390/genes16010006 · Cited by 31
Martini, J.-F., Plimack, E. R., Choueiri, T. K., McDermott, D. F., Puzanov, I. J., Fishman, M., Cho, D. C., Vaishampayan, U. N., Rosbrook, B. P., Fernandez, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1408 · Cited by 29
“Following the favorable results from a phase Ib dose-finding and dose-expansion study in patients with untreated aRCC (19), a phase III randomized trial of combined axitinib and pembrolizumab (axitinib/pembrolizumab) versus sunitinib was initiated which showed benefits in the intent-to-treat population based on all ou…”
BackgroundSelf-citationWu, J., Wang, Y.-C., Xu, W., Luo, W.-J., Wan, F., Zhang, H., Ye, D., Qu, Y.-Y., & Zhu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s272553 · Cited by 27
“Despite immune checkpoint inhibitor therapy, the prognosis of RCC is still unsatisfactory.(3,4) There still exists undefined molecular regulatory networks that promote ccRCC to relapse and metastasize, as well as develop drug resistance.”
BackgroundCheckpoint blockade toxicities: Insights into autoimmunity and treatment
Walsh, M. J., & Dougan, M. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101473 · Cited by 29
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
“The benefit of using this two-pronged approach has been investigated in several cancer types and has been approved as the first-line treatment for advanced renal cell carcinoma (KEYNOTE-426) [180].”
BackgroundQu, Y., Zhang, H., Guo, H., Luo, H., Zou, Q., Xing, N., Xia, S., Sun, Z., Zhang, X., He, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1698 · Cited by 27
Kanesvaran, R., Porta, C., Wong, A. S. C., Powles, T. B., Ng, Q. S., Schmidinger, M., Ye, D., Malhotra, H., Miura, Y., Lee, J. L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100304 · Cited by 30
Self-citationBempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Tannir, N. M., Cho, D. C., Diab, A. K., Sznol, M., Bilen, M. A., Balar, A. V., Grignani, G., Puente-Poushnejad, E., Tang, L., Chien, D. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004419 · Cited by 28
The Emerging Role of Radiation Therapy in Renal Cell Carcinoma
Christensen, M., & Hannan, R. (2022) · Cancers · doi:10.3390/cancers14194693 · Cited by 27
Emerging evidence of immunotherapy for colorectal cancer
Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12633 · Cited by 29
Rossi, A., Aimar, G., Audisio, M., Bungaro, M., Caglio, A., Liello, R. D., Gamba, T., Gargiulo, P., Ghisoni, E., Lombardi, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.008 · Cited by 32
Konishi, S., Hatakeyama, S., Tanaka, T., Ikehata, Y., Tanaka, T. D., Hamano, I., Fujita, N., Yoneyama, T., Yamamoto, H., Yoneyama, T., et al. (2019) · International Journal of Urology · doi:10.1111/iju.14078 · Cited by 27
Manz, K. M., Fenchel, K., Eilers, A., Morgan, J., Wittling, K., & Dempke, W. C. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01167-2 · Cited by 31
Combination drug regimens for metastatic clear cell renal cell carcinoma
Khetani, V. V., Portal, D. E., Shah, M. R., Mayer, T. M., & Singer, E. A. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i8.541 · Cited by 28
Raghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00441-5 · Cited by 26
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Barata, P. C., Gulati, S., Elliott, A., Hammers, H. J., Burgess, E. F., Gartrell, B. A., Darabi, S., Bilen, M. A., Basu, A., Geynisman, D. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178915 · Cited by 26
Tang, C. Z., Sherry, A. D., Seo, A., Hara, K., Choi, H., Liu, S., Sun, X., Montoya, A., Ludmir, E. B., Shah, A. Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00380-8 · Cited by 28
Lactate-mediated histone lactylation promotes melanoma angiogenesis via IL-33/ST2 axis
Zhao, M., Qian, Y., He, L., Peng, T., Wang, H., Wang, X., Jiang, L., Fan, J., Zhang, H., Qu, D., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08023-y · Cited by 31
Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma
Nishida, K., Kawashima, A., Kanazawa, T., Kidani, Y., Yoshida, T., Hirata, M., Yamamoto, K., Yamamoto, Y., Sawada, M., Kato, R., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa004 · Cited by 27
Heo, J. H., Park, C., Ghosh, S., Park, S., Zivkovic, M., & Rascati, K. L. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13282 · Cited by 30
“5 58 134 (70) 110 (57)/82 (43)/0 (0) 94 (49)/84 (44)/7 (4) NR 164 (85) NR”
InfluentialBensalah, K., Bigot, P., Albiges, L. K., Bernhard, J., Bodin, T., Boissier, R., Corréas, J.-M., Gimel, P., Hetet, J. F., Long, J., et al. (2020) · The French Journal of Urology · doi:10.1016/s1166-7087(20)30749-1 · Cited by 28
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Tulchiner, G. A., Pichler, R., Ulmer, H., Staudacher, N., Lindner, A. K., Brunner, A., Zelger, B. G., Steinkohl, F., Aigner, F., Horninger, W., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02882-y · Cited by 29
Canil, C., Kapoor, A., Basappa, N. S., Bjarnason, G. A., Bossé, D., Dudani, S., Graham, J., Gray, S., Hansen, A. R., Heng, D. Y. C., et al. (2021) · Canadian Urological Association Journal · doi:10.5489/cuaj.7245 · Cited by 30
Self-citationCourcier, J., Dalban, C., Laguerre, B., Ladoire, S., Barthélémy, P., Oudard, S. M., Joly, F., Gravis, G., Chevreau, C., Geoffrois, L., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.05.020 · Cited by 26
Tamada, S., Kondoh, C. N., Matsubara, N., Mizuno, R., Kimura, G., Anai, S., Tomita, Y., Oyama, M., Masumori, N., Kojima, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02014-7 · Cited by 27
“Details on the KEYNOTE-426 study design and results of the first interim [10] and extended follow-up [12] analyses have been published previously.”
BackgroundMethodResultSelf-citationAnker, J. F., Miller, J. R., Taylor, N., Kyprianou, N., & Tsao, C. (2021) · Cells · doi:10.3390/cells10113231 · Cited by 28
“On the contrary, ICI efficacy was independent of PD-L1 status in KEYNOTE-426 [27], JAVELIN Renal 101 [28,119], and CheckMate 025 [18].”
BackgroundYoshida, K., Hata, K., Iizuka, J., Kondo, T., Ishihara, H., Ishida, H., Nagashima, Y., Tanabe, K., & Takagi, T. (2022) · In Vivo · doi:10.21873/invivo.12798 · Cited by 26
Minichsdorfer, C., Gleiß, A., Aretin, M., Schmidinger, M., & Fuereder, T. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2070660 · Cited by 29
You, R., Zou, X., Ding, X., Zhang, W., Zhang, M., Wang, X., Xu, H., Liu, Y., Ouyang, Y., Duan, C., et al. (2022) · Med · doi:10.1016/j.medj.2022.07.009 · Cited by 27
Self-citationKnisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 32
Melaiu, O., Vanni, G., Portarena, I., Pistolese, C. A., Anemona, L., Pomella, S., Bei, R., Buonomo, O. C., Roselli, M., Mauriello, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043226 · Cited by 27
Atkins, M. B., Ascierto, P. A., Feltquate, D., Gulley, J. L., Johnson, D. B., Khushalani, N. I., Sosman, J. A., Yap, T. A., Kluger, H. M., Sullivan, R. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005923 · Cited by 31
Self-citationESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
Čufer, T., Kosty, M. P., & on behalf of the Curriculum Development Subgroup—ESMO/ASCO Global Curriculum Working Group (2023) · JCO Global Oncology · doi:10.1200/go.23.00277 · Cited by 39
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.